Searching for
guideline-recommended
genomic information?
Get results fast.
Guide treatment decisions in 7 days*
with Liquid Biopsy.
*Upon sample receipt in the laboratory
High Concordance with Tissue1
for targetable alterations*
before first-line therapy (n=81)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF
High Concordance with Tissue1
for targetable alterations*
before first-line therapy (n=81)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF
Tissue has limitations beyond your control
Tissue has limitations beyond your control
Treatment delays
Results may be unpredictable
and incomplete
Patient burden
Repeated tissue biopsies
may expose patients to
potential adverse events
Finite resource
Tissue exhausted by histopathology stains and PD-L1 testing
Practice/staff burden
Coordination involving
multiple care team members
Relying solely on tissue leads to undergenotyping
~1 in 2 NSCLC patients are unable to get complete genomic results from tissue1
When to use Guardant360®
When to use Guardant360®
Before 1st Line Treatment
Get ahead of the challenges of tissue testing in
advanced NSCLC by utilizing Guardant360 to guide 1L
treatment decisions
At Disease Progression
Get genomic information on over 70+ genes relevant across
multiple solid tumors including MSI-High to help find pan cancer
therapies and clinical trials.
Published Data
Prospective study of 323 NSCLC patients found
Guardant360 improved alteration detection1
Published Data
Prospective study of 323 NSCLC patients found
Guardant360 improved alteration detection1
were unable to get genomic results
from tissue biopsy
had targetable alterations* detected
by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF.
had an objective tumor response or stable disease based on RECIST
were unable to get genomic results
from tissue biopsy
had targetable alterations* detected
by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF.
had an objective tumor response or stable disease based on RECIST
NSCLC comprehensive results in 7 days from sample receipt at the laboratory
Test
with Guardant360® when patient is diagnosed with advanced NSCLC
Get results in 7 days
from sample receipt
at the laboratory to guide treatment decisions
Take action
with first-line
treatment
Findings from NILE Study
Findings from PENN2 Study
Reference:
1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173-180.
MKTAMEA112020_015
NSCLC comprehensive results in 7 days from sample receipt at the laboratory
Test
with Guardant360® when patient is diagnosed with advanced NSCLC
Get results in 7 days
from sample receipt at the laboratory to guide treatment decisions
Take action
with first-line treatment
Address:
21 Biopolis Road,
# 03-28, Nucleos,
Singapore 138567.
Telephone:
+65 6018 8504
WhatsApp Hotline:
+65 8940 0360
Email:
clientservicesamea@guardanthealth.com
biopharma_AMEA@guardanthealth.com
Media inquiries:
Guardant Health Japan Corp.
Address:
9F Tokyo Portcity Takeshiba Office Tower,
1-7-1 Kaigan, Minato-ku,
Tokyo, 105-7590, Japan
© 2023 Guardant Health AMEA ALL RIGHTS RESERVED
